Billionaire Andreas Halvorsen’s 10 Stock Picks With Huge Upside Potential

4. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Upside Potential as of April 28: 54.15%

Viking Global’s Stake Value: $690,858,452

Number of Hedge Fund Holders: 51

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a biopharmaceutical company that develops treatments for rare genetic diseases. Its products include innovative therapies for conditions like phenylketonuria (PKU), hemophilia, and Batten disease. The company targets patients with unmet medical needs, focuses on improving their quality of life, and has a strong presence in the US and Europe.

In the fiscal year 2024, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported record results, with total revenues for the full year reaching $2.85 billion. Fourth quarter results were just as impressive—total revenues reached $747 million, up 16% year-over-year. Much of the income came from VOXZOGO, the company’s treatment for achondroplasia. Strong global demand in Q4 2024 drove 42% growth and 56% full-year growth for the drug’s revenues. Management expects even bigger growth figures in 2025.

According to Alexander Hardy, the company’s President and CEO, “We begin 2025 ready to build on our leadership in treating genetically defined conditions and deliver breakthrough medicines to the patients we serve. This year, we expect a number of innovative pipeline candidates to advance.” This conviction provides the basis for the 2025 guidance, which expects full-year 2025 revenue to be between $3.1 billion and $3.2 billion.

Analysts too carry optimism. On April 21, 2025, Oppenheimer reiterated its Outperform rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shares. The research firm also maintained a $98.00 price target.